**S1 Table. Statistical analysis of the data reported in figures 6 and 9.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Figure 6** | | | |
| interaction | dsRNA treatment | Cry1Ca treatment | Time |
| Haemolymph (H) | | | |
| F2,91=126.99; *P*<0.0001 | F1,91=817.88; *P*<0.0001 | F1,91=4083.84; *P*<0.0001 | F2,91=785.37; *P*<0.0001 |
| Midgut (M) | | | |
| F2,86=0.157; *P*=0.855 | F1,86=0; *P*=0.998 | F1,86=0.898; *P*=0.346 | F2,86=1.528; *P*=0.223 |
| **Figure 9** | | | |
|  | interaction | dsRNA treatment | immune challenge |
| *attacin 1* | F3,56=0.007; *P*=0.999 | F1,56=0.178; *P*=0.675 | F3,56=33.80; *P*<0.0001 |
| *gloverin* | F3,56=0.505; *P*=0.681 | F1,56=0.011; *P*=0.916 | F3,56=146.90; *P*<0.0001 |
| *lysozyme 1a* | F3,56=0.218; *P*=0.884 | F1,56=1.697; *P*=0.198 | F3,56=23.60; *P*<0.0001 |